SG11202102651SA - Farnesoid x receptor agonists and uses thereof - Google Patents
Farnesoid x receptor agonists and uses thereofInfo
- Publication number
- SG11202102651SA SG11202102651SA SG11202102651SA SG11202102651SA SG11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA SG 11202102651S A SG11202102651S A SG 11202102651SA
- Authority
- SG
- Singapore
- Prior art keywords
- farnesoid
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Virology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733004P | 2018-09-18 | 2018-09-18 | |
| US201862733006P | 2018-09-18 | 2018-09-18 | |
| US201962881560P | 2019-08-01 | 2019-08-01 | |
| PCT/US2019/051603 WO2020061113A1 (en) | 2018-09-18 | 2019-09-17 | Farnesoid x receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102651SA true SG11202102651SA (en) | 2021-04-29 |
Family
ID=69887982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102651SA SG11202102651SA (en) | 2018-09-18 | 2019-09-17 | Farnesoid x receptor agonists and uses thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US11084817B2 (https=) |
| EP (2) | EP4596543A3 (https=) |
| JP (1) | JP7554739B2 (https=) |
| KR (2) | KR102810978B1 (https=) |
| CN (1) | CN113056271B (https=) |
| AU (2) | AU2019344903B2 (https=) |
| BR (1) | BR112021004919A2 (https=) |
| CA (1) | CA3112411A1 (https=) |
| CL (1) | CL2021000632A1 (https=) |
| DK (1) | DK3852748T3 (https=) |
| ES (1) | ES3051007T3 (https=) |
| FI (1) | FI3852748T3 (https=) |
| HR (1) | HRP20251321T1 (https=) |
| IL (1) | IL281475B2 (https=) |
| LT (1) | LT3852748T (https=) |
| MA (1) | MA53665B1 (https=) |
| MD (1) | MD3852748T2 (https=) |
| MX (1) | MX2021003110A (https=) |
| PH (1) | PH12021550605A1 (https=) |
| PL (1) | PL3852748T3 (https=) |
| PT (1) | PT3852748T (https=) |
| RS (1) | RS67371B1 (https=) |
| SG (1) | SG11202102651SA (https=) |
| SI (1) | SI3852748T1 (https=) |
| SM (1) | SMT202600076T1 (https=) |
| TW (1) | TWI833805B (https=) |
| WO (1) | WO2020061113A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258763B2 (ja) * | 2017-03-15 | 2023-04-17 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| CA3055990A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| AU2019344903B2 (en) | 2018-09-18 | 2025-02-27 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| CN120732855A (zh) * | 2020-03-18 | 2025-10-03 | 伊莱利利公司 | 用于治疗疾病的法尼醇x受体激动剂 |
| WO2021188695A1 (en) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| KR20220155356A (ko) * | 2020-03-18 | 2022-11-22 | 메타크린, 인크. | 파르네소이드 x 수용체 효능제의 결정형 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| CN116554121A (zh) * | 2023-05-05 | 2023-08-08 | 济南悟通生物科技有限公司 | 一种2-异丁基噻唑的合成方法 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069810A1 (en) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6645980B1 (en) | 2000-05-25 | 2003-11-11 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| JP2003500392A (ja) | 1999-05-25 | 2003-01-07 | セプラコール， インク． | 複素環式鎮痛性化合物およびその使用方法 |
| US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
| IL154363A0 (en) | 2000-09-25 | 2003-09-17 | Actelion Pharmaceuticals Ltd | Substituted amino-aza-cycloalkanes useful against malaria |
| FR2815032B1 (fr) | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
| FR2825706B1 (fr) | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
| FR2839974B1 (fr) | 2002-05-24 | 2004-07-16 | Pf Medicament | Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament |
| AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| BR0314126A (pt) | 2002-09-20 | 2005-06-28 | Pfizer Prod Inc | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio |
| WO2004046162A2 (en) | 2002-11-14 | 2004-06-03 | The Scripps Research Institute | Non-steroidal fxr agonists |
| US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| US7647217B2 (en) | 2002-11-15 | 2010-01-12 | The Salk Institute For Biological Studies | Structure of the farnesoid X receptor ligand binding domain and methods of use therefor |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1648874B1 (en) | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| WO2005058822A1 (en) | 2003-12-17 | 2005-06-30 | Actelion Pharmaceuticals Ltd | Substituted amino-cycloalkanes |
| WO2005097760A1 (en) | 2004-03-26 | 2005-10-20 | Rigel Pharmaceuticals, Inc. | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| JP2006199656A (ja) | 2005-01-24 | 2006-08-03 | Kowa Co | アミド基を有する環状アミン化合物 |
| MY144229A (en) | 2006-01-26 | 2011-08-15 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use as therapeutic agents |
| EP2001851A2 (en) | 2006-03-28 | 2008-12-17 | Novartis AG | Amide derivatives and their application for the treament of g protein related diseases |
| US20080081824A1 (en) | 2006-09-29 | 2008-04-03 | Bristol-Myers Squibb Company | Substituted piperidines as modulators of chemokine receptor activity |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| WO2010001869A1 (ja) | 2008-06-30 | 2010-01-07 | 武田薬品工業株式会社 | ４置換ベンゼン化合物およびその用途 |
| JP2010077109A (ja) | 2008-08-28 | 2010-04-08 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| EP2454243A2 (en) | 2009-07-15 | 2012-05-23 | Merck Serono SA | Tetrazole derivatives |
| CA2767089A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| FR2963005B1 (fr) | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
| ME02754B (me) | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP2732871A4 (en) | 2011-07-13 | 2015-03-04 | M Tech Co Ltd | PROCESS FOR PRODUCING MICROPARTICLES WITH CONTROLLED CRYSTALLITE DIAMETER |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| GB201316824D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| EP3116851B1 (en) | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogs of fexaramine and methods of making and using |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| KR20160132111A (ko) | 2014-03-13 | 2016-11-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Fxr 작용제와 제조방법 및 용도 |
| US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
| US20180116993A1 (en) | 2015-01-22 | 2018-05-03 | Xiamen University | Modulators of farnesoid x receptor and methods for the use thereof |
| AU2016233579A1 (en) | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| WO2017018751A1 (ko) | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| US10626081B2 (en) | 2015-09-16 | 2020-04-21 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
| WO2017049177A1 (en) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US10703712B2 (en) * | 2015-09-16 | 2020-07-07 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
| EP3350164A4 (en) | 2015-09-16 | 2019-03-27 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| CN105477636B (zh) * | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| CN107126419B (zh) | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| WO2017170182A1 (ja) | 2016-03-31 | 2017-10-05 | 株式会社Adeka | 感光性組成物及び新規化合物 |
| WO2018170167A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20200131129A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| JP7258763B2 (ja) * | 2017-03-15 | 2023-04-17 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| CA3055990A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2018170165A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CZ2017298A3 (cs) | 2017-05-26 | 2018-12-05 | Zentiva, K.S. | Amorfní formy obeticholové kyseliny |
| WO2020060007A1 (ko) | 2018-09-17 | 2020-03-26 | 엘지전자 주식회사 | 5g 이동통신에서 pdu 세션을 핸들링하는 방법 및 무선 기기 |
| JP2022500393A (ja) | 2018-09-18 | 2022-01-04 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| WO2020061116A1 (en) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2020061118A1 (en) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3852749A4 (en) | 2018-09-18 | 2022-08-24 | Metacrine, Inc. | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST |
| CN113056264A (zh) | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 法尼醇x受体激动剂及其用途 |
| AU2019344903B2 (en) | 2018-09-18 | 2025-02-27 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| EA202190661A1 (ru) | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| CN120732855A (zh) | 2020-03-18 | 2025-10-03 | 伊莱利利公司 | 用于治疗疾病的法尼醇x受体激动剂 |
| WO2021188695A1 (en) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| KR20220155356A (ko) | 2020-03-18 | 2022-11-22 | 메타크린, 인크. | 파르네소이드 x 수용체 효능제의 결정형 |
-
2019
- 2019-09-17 AU AU2019344903A patent/AU2019344903B2/en active Active
- 2019-09-17 CA CA3112411A patent/CA3112411A1/en active Pending
- 2019-09-17 WO PCT/US2019/051603 patent/WO2020061113A1/en not_active Ceased
- 2019-09-17 LT LTEPPCT/US2019/051603T patent/LT3852748T/lt unknown
- 2019-09-17 MA MA53665A patent/MA53665B1/fr unknown
- 2019-09-17 EP EP25178478.1A patent/EP4596543A3/en active Pending
- 2019-09-17 PL PL19862391.0T patent/PL3852748T3/pl unknown
- 2019-09-17 MX MX2021003110A patent/MX2021003110A/es unknown
- 2019-09-17 HR HRP20251321TT patent/HRP20251321T1/hr unknown
- 2019-09-17 TW TW108133441A patent/TWI833805B/zh active
- 2019-09-17 DK DK19862391.0T patent/DK3852748T3/da active
- 2019-09-17 PT PT198623910T patent/PT3852748T/pt unknown
- 2019-09-17 SG SG11202102651SA patent/SG11202102651SA/en unknown
- 2019-09-17 SI SI201930976T patent/SI3852748T1/sl unknown
- 2019-09-17 US US16/573,993 patent/US11084817B2/en active Active
- 2019-09-17 JP JP2021513407A patent/JP7554739B2/ja active Active
- 2019-09-17 BR BR112021004919-3A patent/BR112021004919A2/pt unknown
- 2019-09-17 EP EP19862391.0A patent/EP3852748B1/en active Active
- 2019-09-17 IL IL281475A patent/IL281475B2/en unknown
- 2019-09-17 MD MDE20210696T patent/MD3852748T2/ro unknown
- 2019-09-17 SM SM20260076T patent/SMT202600076T1/it unknown
- 2019-09-17 CN CN201980075902.2A patent/CN113056271B/zh active Active
- 2019-09-17 ES ES19862391T patent/ES3051007T3/es active Active
- 2019-09-17 KR KR1020217011359A patent/KR102810978B1/ko active Active
- 2019-09-17 RS RS20251101A patent/RS67371B1/sr unknown
- 2019-09-17 KR KR1020257016139A patent/KR20250073553A/ko active Pending
- 2019-09-17 FI FIEP19862391.0T patent/FI3852748T3/fi active
-
2021
- 2021-03-16 CL CL2021000632A patent/CL2021000632A1/es unknown
- 2021-03-17 PH PH12021550605A patent/PH12021550605A1/en unknown
- 2021-06-16 US US17/349,757 patent/US11773094B2/en active Active
-
2023
- 2023-07-17 US US18/353,659 patent/US20230382913A1/en not_active Abandoned
-
2024
- 2024-10-31 US US18/933,587 patent/US20250289821A1/en active Pending
-
2025
- 2025-05-22 AU AU2025203804A patent/AU2025203804A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269065A (en) | Paranoid X receptor agonists and uses thereof | |
| IL269068A (en) | Paranoid X receptor agonists and uses thereof | |
| IL281471A (en) | Farnesoid x receptor agonists and uses thereof | |
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224A (en) | 1-GLP agonist receptors and their use | |
| SG11202102651SA (en) | Farnesoid x receptor agonists and uses thereof | |
| ZA201801750B (en) | Farnesoid x receptor agonists and uses thereof | |
| IL281474A (en) | Farnesoid x receptor agonists and uses thereof | |
| ZA201904616B (en) | Glp-1 receptor agonists and uses thereof | |
| SG11202103609YA (en) | T-cell receptors and uses thereof | |
| IL277144A (en) | Adenosine receptor antagonists and uses thereof | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| EP3627631A4 (en) | NETWORK DEVICE AND LENGTH INTERFACE |